Panacea Biotec appoints Vinod Goel as CFO from December 16, 2025

Management Changes View source PDF Explain this filing

PANACEABIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.3%Reaction day

₹356.30

prior close

₹358.20

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.6%-0.7% vs market

Pharmaceuticals peers, median of 159sector-0.4%-0.9% vs sector

On the reaction day the stock moved 0.7 pts less than Nifty Microcap 250 and 0.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.5

10m

-1.5

15m

-1.0

30m

-0.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.3-0.6-0.7-0.4-0.9

Next day

-2.3-1.5-0.8-1.2-1.1

-3.2-1.8-1.3-1.3-1.9

-0.2-0.6+0.4-0.4+0.2

+0.7+0.8-0.1+0.1+0.6

+0.1+0.8-0.7+0.3-0.1

+14.8-0.2+15.0-0.7+15.5

15d

+7.5+1.1+6.4+0.9+6.6

+12.5-3.5+16.0-2.6+15.1

-2.6-3.2+0.6-4.3+1.7

-10.7-12.8+2.1-11.5+0.9

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 159Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Panacea Biotec has appointed Mr. Vinod Goel as Chief Financial Officer effective December 16, 2025, replacing Mr. Devender Gupta who resigned as CFO effective December 15, 2025. Mr. Goel was already serving as Group CFO and Head Legal and Company Secretary, and has over 35 years of experience. He will now be designated as Group CFO and Head Legal and Corporate Governance. Separately, Mr. Ankit Jain has been appointed as Company Secretary and Compliance Officer, replacing Mr. Goel in that role. Both appointments were approved by the Nomination and Remuneration Committee and Audit Committee.

Likely market impact

Smooth internal succession at the CFO level, with a long-tenured insider taking over. Minimal disruption expected, continuity in finance and governance functions maintained.